ArticleRheumatology (Oxford, England)2025

Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply.

Kornelis S M van der Geest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.